Form 4: Pfizer Director James Quincey Reports Acquisition of Phantom Stock Units

Director James Quincey reports acquisition of phantom stock units representing deferred director's compensation.

Summary

• On March 31, 2025, James Quincey, a director of Pfizer Inc., acquired 1,529.203 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price per share for the underlying common stock is $25.34.
• Following the transaction, Mr. Quincey beneficially owns 57,443.047 shares of common stock directly.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, providing transparency into the compensation and holdings of Pfizer's directors. It's standard practice for directors to receive deferred compensation in the form of stock units.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves deferred compensation for a director.
• It provides transparency to shareholders regarding director compensation.

Key Dates

Keywords

Form 4, insider trading, director compensation, phantom stock units, James Quincey, PFE, Pfizer